Global Osteoarthritis Gene Therapy Market is valued approximately USD XX billion in 2020 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2021-2027. Osteoarthritis is a type of arthritis. arthritis affects millions of people worldwide. It occurs due to wear down of the protective cartilage that cushions the ends of the bones. The disorders most commonly affects joints in your hands, knees, hips, and spine. Rising prevalence of Osteoarthritis and increasing geriatric population are key driver for the growth of Osteoarthritis Gene Therapy. According to The Centers for Disease Control and Prevention's estimates 1 in 4 (or 54.4 million) US adults have some form of arthritis, this figure is projected to reach 78 million by the year 2040 from 63 million in year 2020. As per Database company Statista's estimates in 2019, the incidence of osteoarthritis of the knee in Europe was approximately 576 per 100,000 females and 419 per 100,000 males, making it the most common location of osteoarthritis. Furthermore, osteoarthritis of the hand occurred in 226 women per 100,000 and 134 men per 100,000. Also, with the surging healthcare infrastructure in emerging economies and rising technological advancements in field of Osteoarthritis Gene Therapy, the adoption & demand for Osteoarthritis Gene Therapy is likely to increase the market growth during the forecast period. However, high treatment cost of Osteoarthritis Gene Therapy impedes the growth of the market over the forecast period of 2021-2027.

The key regions considered for the global Osteoarthritis Gene Therapy market study includes Asia Pacific, North America, Europe, Latin America and Rest of the World. Europe is the leading/significant region across the world in terms of market share owing to rising prevalence of osteoarthritis cases in the region. Whereas North America is anticipated to exhibit highest growth rate / CAGR over the forecast period 2021-2027. Factors such as increasing government investments in various R&D activities in cell-based research would create lucrative growth prospects for the Osteoarthritis Gene Therapy market across Asia-Pacific region.

Major market player included in this report are:

Flexion

GeneQuine

Novartis

Smith & Nephew

Genascence

Kolon TissueGene

Sanofi

Paraxel

Medipost co ltd

Mundipharma.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Site of Injection:

Synovium

Cartilage

By Vectors:

Non-viral

Retrovirus

Lentivirus

Adenovirus

Adeno-associated virus (AAV)

HSV

By End Use Industries:

Hospitals and clinics

Orthopedic Centers

Assisted living Facilities

Nursing Homes

Ambulatory Surgical Centers

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019

Base year - 2020

Forecast period - 2021 to 2027

Target Audience of the Global Osteoarthritis Gene Therapy Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors